New ESMO scale ranks mutations as cancer medicine targets

Fricker Janet

首页> 外文期刊>The lancet oncology >New ESMO scale ranks mutations as cancer medicine targets

【24h】

New ESMO scale ranks mutations as cancer medicine targets

机译：新的ESMO规模将突变排名为癌症药物目标

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2018年第10期|共1页
作者
Fricker Janet;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. New ESMO scale ranks mutations as cancer medicine targets [J] . Fricker Janet The lancet oncology . 2018,第10期

机译：新的ESMO规模将突变排名为癌症药物目标
2. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations [J] . Giuliani Jacopo, Remo Andrea, Bonetti Andrea Expert review of pharmacoeconomics & outcomes research . 2017,第1a3期

机译：欧洲医学肿瘤医学初级社会临床益处（ESMO-MCBS）在一线中施用酪氨酸激酶抑制剂的托源激酶抑制剂的枢转期III随机对照试验，其具有激活表皮生长因子受体突变的先进非小细胞肺癌
3. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: A position paper by the European Society for Medical Oncology (ESMO) [J] . CiardielloF., ArnoldD., CasaliP.G., Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第9期

机译：在当今和未来的肿瘤学中提供精确医学-个性化癌症医学的前景和挑战：欧洲医学肿瘤学会（ESMO）的立场文件
4. CONTROLLED RELEASE AND TUMOUR-TARGETED ANTI-TUMOUR MEDICINES: A REVIEW OF THE CURRENT USE AND FUTURE POTENTIAL IN CANCER CHEMOTHERAPY [C] . R. Duncan Proceedings of the 29th Annual Meeting of the Controlled Release Society . 2002

机译：控制释放和靶向肿瘤的抗肿瘤药物：癌症化疗的当前使用和未来潜力的回顾
5. Adipsin Is an ERα Target Gene that Leads to Endocrine Resistance in Breast Cancer with ESR1 Mutations [D] . Malone, Marie Kathryn. 2020

机译：Adipsin是一种ERα靶基因，导致ESR1突变的乳腺癌内分泌抵抗力
6. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) [O] . J Mateo, D Chakravarty, R Dienstmann, -1

机译：将基因组改变列为癌症精密医学靶标的框架：分子靶标临床可操作性的ESMO量表（ESCAT）
7. CA2 The Esmo Magnitude of Clinical Benefit Scale for Novel Cancer Medicines — Correspondence with Prioritization Decisions In Updating the Israeli National List of Health Services [O] . Hammerman A, Greenberg-Dotan S, Feldhamer I, 2015

机译：CA2新型抗癌药物的临床效益量表的Esmo幅度—与更新以色列国家卫生服务清单的优先级决定相对应
8. Development of Targeted Molecular Therapy for Cancers Harboring BAP1 Mutations. [R] . Harbour, J. W., Kuznetsov, J., King, M. L., 2016

机译：针对携带Bap1突变的癌症的靶向分子疗法的开发。

New ESMO scale ranks mutations as cancer medicine targets

著录项

相似文献

相关主题

期刊订阅